NCT07366086
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 2 words
- Trial sites expanded: 4 → 9 locations
- Minor Primary and study completion moved earlier from May 21, 2028 to Apr 19, 2028v5
- Minor Study sites: 3 to 4v4
- Minor Study sites: 2 to 3v3
- Notable Recruitment opened
- Study sites: 0 to 2
- Start date changed from estimate of Mar 7, 2026 to Mar 18, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Adverse Events (AEs)
Timeframe: Up to 9 months
Arms and interventions
Standard of CareOther
Participants who completed romosozumab trial 20200105 will continue to receive standard of care treatment (calcium and vitamin D), as determined by the investigator and local guidance. No investigational drug product will be administered in this trial as this is a safety follow-up.
Dietary supplements: Vitamin D, Calcium
Sites
9 sites in 6 countries
United States 3, Germany 2, Belgium 1, China 1, Hungary 1, Japan 1